Additional Information

Description

Fluzone® 2025–2026 (Flu-111) is an inactivated quadrivalent influenza vaccine formulated for active immunization against influenza A and B strains expected during the 2025–2026 flu season. It contains hemagglutinin antigens from two A strains and two B strains, aligning with the annual recommendations from the World Health Organization (WHO). 

This vaccine is produced using egg-based technology and is designed to protect individuals aged 6 months and older. The vaccine is presented in 0.5 mL prefilled syringes, with each box containing 10 doses. Each 0.5 mL dose is administered via intramuscular injection, typically into the deltoid muscle for adults and into the anterolateral thigh for younger children. The prefilled syringe eliminates the need for reconstitution, ensuring ease of administration and reducing the risk of dosing errors. 

Common side effects associated with Fluzone® include injection site pain, swelling, redness, fatigue, headache, and muscle aches. Serious adverse events are rare but may include anaphylaxis and Guillain-Barré syndrome. The vaccine is contraindicated in individuals with a history of severe allergic reactions to any component of the formulation or prior doses of the vaccine.